HomeStructural heart diseaseValvular Aortic Valve

Valvular Aortic Valve

ACC 2021 | ATLANTIS 4D-CT: Apixaban and Sub-Clinical Thrombosis After TAVR

Indicating apixaban after transcatheter aortic valve replacement (TAVR) does not significantly reduce the risk of sub-clinical leaflet...

ACC 2021 | ATLANTIS: Apixaban After TAVR vs. Standard of Care

Adding apixaban to the treatment of patients undergoing transcatheter aortic valve replacement (TAVR) was non-superior to standard...

Is Rheumatic Etiology Counter Indicated for TAVR?

Patients with rheumatic aortic stenosis have been systematically excluded from all studies on transcatheter aortic valve replacement...

Validating Consensus on Post TAVR Conduction Disturbances in the Clinical Practice

Little over a year ago, JACC published the expert consensus on the management of post transcatheter aortic...

Watch again our Webinar on TAVR in Low-Risk Patients

Watch again our Webinar on "TAVR in Low-Risk Patients" on our Youtube account. The event was held...

ST-Segment Elevation Infarction After TAVR: Problems in Every Aspect

For interventional cardiologists, treating an ST-segment elevation infarction in a patient with transcatheter aortic valve replacement (TAVR)...

SOLVE-TAVI after 12-month followup: self-expanding vs. balloon expandable and general vs. local anesthesia

The ambitious SOLVE-TAVI (soon to be published in JACC) is aimed at answering to of the most...